Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

• Published in: Autoimmunity reviews Vol. 19; no. 1; p. 102429
• Main Authors: Ruiz de Morales, José María G., Puig, Lluís, Daudén, Esteban, Cañete, Juan D., Pablos, José Luis, Martín, Antonio Olveira, Juanatey, Carlos González, Adán, Alfredo, Montalbán, Xavier, Borruel, Natalia, Ortí, Guillermo, Holgado-Martín, Esther, García-Vidal, Carolina, Vizcaya-Morales, Cynthia, Martín-Vázquez, Víctor, González-Gay, Miguel Ángel
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-01-2020
• Subjects: Arthritis, Psoriatic; Arthritis, Rheumatoid; Biological drugs; Citoquine; Humans; IL17A; Immunology; Inflammation; Interleukin-17 - antagonists & inhibitors; Interleukin-17 - immunology; Psoriasis; Spondylitis, Ankylosing; Inflammation; Immunology; Citoquine; Psoriasis; Biological drugs; IL17A
• ISSN: 1568-9972; 1568-9972; 1873-0183
• DOI: 10.1016/j.autrev.2019.102429

Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a molecular target for the development of novel biological therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease, uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future research.